IKBKE and breast carcinoma: Further validation of the IKBKE inhibitor was performed in HCC1143 cells, and also in these cells, the Amlexanox treatment inhibited the stiffness-induced malignant breast cancer cell phenotype (Fig. 4e, top row) and proliferation (Fig. 4e, bottom row).